440100-94-7

Basic information

• Product Name: 2-bromothiazole-5-carbonitrile
• Synonyms: 2-bromothiazole-5-carbonitrile;2-Bromo-5-cyanothiazole;2-broMo-1,3-thiazole-5-carbonitrile;2-BroMo-5-thiazolecarbonitrile
• CAS NO: 440100-94-7
• Molecular Formula: C₄HBrN₂S
• Molecular Weight: 189.04
• Mol File: 440100-94-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 276.1 °C at 760 mmHg
• Flash Point: 120.8 °C
• Appearance: /
• Density: 1.97 g/cm³
• Vapor Pressure: 0.0049mmHg at 25°C
• Refractive Index: 1.65
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.28±0.10(Predicted)
• CAS DataBase Reference: 2-bromothiazole-5-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromothiazole-5-carbonitrile(440100-94-7)
• EPA Substance Registry System: 2-bromothiazole-5-carbonitrile(440100-94-7)

Safety Data

• Hazardous Substances Data: 440100-94-7(Hazardous Substances Data)

Usage

General Description

2-bromothiazole-5-carbonitrile is a chemical compound that belongs to the thiazole family. It is composed of a thiazole ring with a bromine atom at position 2 and a cyano group (carbonitrile) at position 5. 2-bromothiazole-5-carbonitrile is commonly used in organic synthesis as a versatile building block for the construction of more complex molecules. It has been studied for its potential pharmacological properties and has been used as a precursor in the synthesis of pharmaceuticals and agrochemicals. Additionally, 2-bromothiazole-5-carbonitrile has been investigated for its potential as a reactive intermediate in various chemical reactions. Overall, this compound has a wide range of applications in the field of organic chemistry and drug discovery.

InChI:InChI=1/C4HBrN2S/c5-4-7-2-3(1-6)8-4/h2H

Upstream product

• 848499-31-0 2-bromothiazole-5-carboxamide 
• 51640-52-9 2-amino-5-cyanothiazole 

Downstream Products

• 440102-56-7 2-amino-N-(5-cyano-2-thiazolyl)-2-methylpropylamine 
• 898258-72-5 2-(piperazin-1-yl)thiazole-5-carbonitrile 

Relevant articles and documents

Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series

Inhibition of stearoyl-CoA desaturase (SCD) activity represents a potential novel mechanism for the treatment of metabolic disorders including obesity and type II diabetes. To circumvent skin and eye adverse events observed in rodents with systemically-distributed SCD inhibitors, our research efforts have been focused on the search for new and structurally diverse liver-targeted SCD inhibitors. This work has led to the discovery of novel, potent and structurally diverse liver-targeted bispyrrolidine SCD inhibitors. These compounds possess suitable cellular activity and pharmacokinetic properties to inhibit liver SCD activity in a mouse pharmacodynamic model.

HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, C═CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desat- urase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.